A study investigating the safety of Tysabri in patients with early relapsing-remitting MS has been presented at the 2016 meeting of the Consortium of Multiple Sclerosis Centres (CMSC).
Previous studies showed that highly effective MS therapies improve patients’ clinical outcomes. However, recent reports suggested treatment with Tysabri was associated with a significant increase in antibodies against the John Cunningham (JC) virus, which causes the rare and sometimes fatal disease progressive multifocal leukoencephalopathy (PML).
The clinical trial STRIVE was designed to determine the proportion of patients negative for anti-JC virus antibodies and with relapsing-remitting MS (RRMS) who have initiated Tysabri treatment early in their disease course and showed no evidence of disease activity (NEDA) at months 12 and 24.
A one-year interim analysis of 174 patients enrolled in the STRIVE trial revealed the majority of the patients (54.9 percent) had reached a NEDA state. Moreover, researchers noted the adverse event profile was consistent with the well-established safety profile previously described for Tysabri.
In conclusion, the results support the concept that MS patients treated early in their disease course with Tysabri can reach NEDA.
Source: Multiple Sclerosis News Today, 06 June 2016, Patricia Inacio PHD